Business Wire

New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis

Del

A diagnosis of IPF is news that few patients want to hear from their physician, but the reality is that approximately 3 million people worldwide are living with idiopathic pulmonary fibrosis (IPF). It’s a rare and devastating disease with a median life expectancy after diagnosis of approximately 2-3 years.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160920006002/en/

IPF patient survey infographic (Photo: Business Wire)hh

IPF patient survey infographic (Photo: Business Wire)hh

As with the diagnosis of any life-threatening disease, it can be a distressing and emotional experience for patients and their families. It is a time when it can be difficult to take the news in as well as remember/understand the information shared by a doctor.

In positive news, today results of a new global survey supported by Boehringer Ingelheim of over 120 patients with IPF show that 9 out of 10 patients were happy with the way their doctor informed them of their diagnosis.

However, a group of patients in the survey revealed there was additional information that would have been helpful to have received at that time. These include information about support, treatment and the realities of living with IPF:

  • 60% of patients would like to have known what other support was available to help with their IPF
  • 60% wanted to know if IPF requires long-term treatment and how effective those treatments are
  • 50% of patients wanted an insight into the realities of living with IPF over the long term
  • 50% wanted an understanding of how their IPF would progress after treatment initiation, including if they will need to take oxygen

“A diagnosis of IPF is devastating for the patient, their partner, for everyone. It is very reassuring to see from this survey that these patients felt positive about how their physician managed their diagnosis discussion,” said Klaus Geissler, European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF). “But we know that when patients are stressed and anxious that they can forget or not understand key parts of the conversation they have with their physician: it’s helpful for us to see that patients are keen to have more information about the support that will be available to them and details of treatment moving forward. I would recommend patients involve their families in the first interview with their physician in order to better understand and remember the discussion around diagnosis.”

The new global survey of 121 patients with IPF follows a 2015 global survey of over 400 pulmonologists. Both surveys were designed to provide insights into IPF and the realities of living with the condition.

The new results revealed that the priorities for patients after being diagnosed with IPF closely matched what physicians believed their patients’ priorities were at that time.

  • The top three priorities for patients were: seeing an IPF specialist (26%), getting information about the disease (21%) and initiation of an effective treatment (18%).
  • The top three priorities physicians believed their patients had were: getting information about the disease (35%), initiating an effective treatment (23%) and seeing an IPF specialist (21%).

In addition, when patients were asked what was most important to them in knowing how IPF will affect them, ‘Knowing what treatment options are available to me’ was the top choice for patients (77%). In the 2015 pulmonologist survey, this was also the top choice for what physicians believed was most important to patients (77%).

“As a physician it’s encouraging to see the majority of patients happy with how they were informed about their IPF diagnosis,” said Dr. Marlies Wijsenbeek, pulmonologist, Erasmus MC, The Netherlands. “But good communication doesn’t stop there – we need to understand what patients wish to know and take into consideration their level of understanding. Seeing that physicians’ understanding of patients’ priorities are truly aligned with what patients report to be their priorities is a great first step to achieving this.”

At Boehringer Ingelheim we recognise the importance of sharing information so that patients and their families are informed about this serious disease. To coincide with the launch of the survey results, we are pleased to also share ‘Life with IPF – an eBook’. Available on www.LifewithIPF.com the e-book describes the IPF patient journey, from diagnosis and what to expect, through to management options and helpful resources and tips.

Also available through Google Play: https://bit.ly/2czw8Zi and iTunes: apple.co/2cLuw0a

Stay tuned for the next insights from the survey in early 2017 to coincide with Rare Disease Day 2017.

~ ENDS ~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/new-survey-about-ipf-diagnosis

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Steeper Energy Announces EUR 50.6 M (DKK 377 M) Advanced Biofuel Project with Norwegian-Swedish joint venture Silva Green Fuel in Licensing Deal18.12.2017 07:00Pressemelding

Steeper Energy, a Danish-Canadian clean-fuel company, is partnering with Silva Green Fuel, a Norwegian-Swedish joint venture, to construct a EUR 50.6 M (DKK 377M) industrial scale demonstration plant at a former pulp mill located in Tofte, Norway leading to a future commercial scale project. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005029/en/ Steeper will license its proprietary Hydrofaction™ technology to Silva, who will build the facility over the next 18 months. The demonstration plant will use woody residues as feedstock that are converted to renewable crude oil and, in turn, will be upgraded to renewable diesel, jet or marine fuel. Steeper’s Hydrofaction™ technology was selected by Silva after an exhaustive due diligence review of some 40 other technologies. Hydrofaction™ harnesses water

Yokogawa Develops N-IO Standard Field Enclosure and Control System Virtualization Platform18.12.2017 02:00Pressemelding

Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed an N-IO standard field enclosure and a control system virtualization platform. The enclosure is a weatherproof remote IO cabinet that stores IO devices used by the CENTUM(R) VP integrated production control system and the ProSafe(R)-RS safety instrumented system, and the virtualization platform enables the control of multiple virtual devices on a single server. By reducing the amount of time and effort to engineer a new system, these solutions help to both speed up project execution and reduce total cost of ownership (TCO). The N-IO standard field enclosure is scheduled to be released in February 2018, and the virtualization platform will be released in May 2018. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005010/en/ N-I

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13Pressemelding

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21Pressemelding

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38Pressemelding

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom